Praxis Precision climbs after FDA's 'breakthrough' tag for tremor drug

Praxis Precision Medicines

29/12/2025 13:25

** Shares of drug developer Praxis Precision Medicines PRAX.O rise 11.5% to $299.9 premarket

** PRAX says U.S. Food and Drug Administration has granted "breakthrough" tag for its experimental drug, ulixacaltamide, to treat patients with essential tremor

** The breakthrough therapy tag is meant to speed up development and review of drugs to treat a serious condition or those with unmet medical need

** Essential tremor is a neurological movement disorder that causes involuntary, rhythmic shaking in hands, arms, head or voice

** As of last close, stock has more than tripled YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))